Menu Search
Equities

BRAIN Biotech AG

BNNX.N:GER

BRAIN Biotech AG

Actions
Basic MaterialsChemicals
  • Price (EUR)2.93
  • Today's Change-0.02 / -0.68%
  • Shares traded13.02k
  • 1 Year change-28.19%
  • Beta1.1723
Data delayed at least 15 minutes, as of Nov 14 2024 16:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 6 analysts offering 12 month price targets for BRAIN Biotech AG have a median target of 6.90, with a high estimate of 10.00 and a low estimate of 5.20. The median estimate represents a 135.49% increase from the last price of 2.93.
High241.3%10.00
Med135.5%6.90
Low77.5%5.20

Earnings history & estimates in EUR

BRAIN Biotech AG reported annual 2023 losses of -0.38 per share on Jan 17, 2024.
Average growth rate+3.90%
More ▼

Revenue history & estimates in EUR

of 14.94m.
Average growth rate+3.57%
B.R.A.I.N. Biotechnology Research and Information Network AG had revenues for the full year 2023 of 55.34m. This was 11.77% above the prior year's results.
Average growth rate+10.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.